Incidence of new fractures in older patients with osteoporosis receiving biosimilar teriparatide or reference products: A retrospective cohort study
The biosimilar teriparatide showed effectiveness and safety comparable with those of the reference products in treating osteoporosis patients. Our results suggest that clinicians need not hesitate to prescribe biosimilar teriparatide for osteoporosis patients.
Authors
- So Sato (ORCID: https://orcid.org/0000-0003-1265-6835)
- Akira Okada (ORCID: https://orcid.org/0000-0001-6480-3388)
- Yusuke Sasabuchi (ORCID: https://orcid.org/0000-0001-7828-0549)
- Hideo Yasunaga (ORCID: https://orcid.org/0000-0002-6017-469X)
Institutions
- The University of Tokyo (JP)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-09-08
- DOI
- https://doi.org/10.1111/bcp.16243
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- Ministry of Health, Labour and Welfare